{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:26:30Z","timestamp":1786767990856,"version":"build-2736575974"},"reference-count":52,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,8,10]]},"DOI":"10.1253\/circrep.cr-26-0054","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:09:44Z","timestamp":1782252584000},"page":"1326-1336","source":"Crossref","is-referenced-by-count":0,"title":["Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib"],"prefix":"10.1253","volume":"8","author":[{"given":"Hiroshi","family":"Kadowaki","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Umei","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"},{"name":"International Medical Center of Zhongshan Hospital, Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo"},{"name":"Cardiovascular Biobank Research Center, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"},{"name":"Molecular Cardiovascular Medicine, Division of Innovative Research, Project Research Center, Medical Research Institute, Kanazawa Medical University"},{"name":"Multidisciplinary Cancer Center, Kanazawa Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. <i>Nature<\/i> 2011; 473: 298\u2013307.","DOI":"10.1038\/nature10144"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: Current status and future directions. <i>Lancet<\/i> 2016; 388: 518\u2013529.","DOI":"10.1016\/S0140-6736(15)01088-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. <i>Nat Rev Drug Discov<\/i> 2007; 6: 734\u2013745.","DOI":"10.1038\/nrd2380"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. <i>Lancet<\/i> 2006; 368: 1329\u20131338.","DOI":"10.1016\/S0140-6736(06)69446-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. <i>N Engl J Med<\/i> 2007; 356: 115\u2013124.","DOI":"10.1056\/NEJMoa065044"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>N Engl J Med<\/i> 2011; 364: 501\u2013513.","DOI":"10.1056\/NEJMoa1003825"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. <i>J Clin Oncol<\/i> 2023; 41: 1965\u20131971.","DOI":"10.1200\/JCO.22.02623"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: A scientific statement from the American Heart Association. <i>Hypertension<\/i> 2023; 80: e46\u2013e57.","DOI":"10.1161\/HYP.0000000000000224"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. <i>Acta Oncol<\/i> 2009; 48: 9\u201317.","DOI":"10.1080\/02841860802314720"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Waliany S, Sainani KL, Park LS, Zhang CA, Srinivas S, Witteles RM. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor. <i>JACC CardioOncol<\/i> 2019; 1: 24\u201336.","DOI":"10.1016\/j.jaccao.2019.08.012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. <i>Cancer<\/i> 2015; 121: 311\u2013319.","DOI":"10.1002\/cncr.28972"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, et al. Both new-onset and pre-existing hypertension indicate favorable clinical outcomes in patients treated with anti-vascular endothelial growth factor therapy. <i>Circ J<\/i> 2024; 88: 217\u2013225.","DOI":"10.1253\/circj.CJ-22-0628"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. <i>Hypertension<\/i> 2017; 70: 220\u2013226.","DOI":"10.1161\/HYPERTENSIONAHA.117.08856"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. <i>J Am Soc Hypertens<\/i> 2018; 12: 409\u2013425.","DOI":"10.1016\/j.jash.2018.03.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: Vascular endothelial growth factor inhibitors and hypertension. <i>Cardiovasc Res<\/i> 2019; 115: 904\u2013914.","DOI":"10.1093\/cvr\/cvz022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mukai M, Komori K, Oka T. Mechanism and management of cancer chemotherapy-induced atherosclerosis. <i>J Atheroscler Thromb<\/i> 2018; 25: 994\u20131002.","DOI":"10.5551\/jat.RV17027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. le Noble FAC, Mourad JJ, Levy BI, Struijker-Boudier HAJ. VEGF (vascular endothelial growth factor) inhibition and hypertension: Does microvascular rarefaction play a role? <i>Hypertension<\/i> 2023; 80: 901\u2013911.","DOI":"10.1161\/HYPERTENSIONAHA.122.19427"},{"key":"18","unstructured":"18. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human Services; 2017 [cited 2026 Feb 16]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Revised_Redirect.pdf."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). <i>Eur J Cancer<\/i> 2009; 45: 228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. <i>Ann Oncol<\/i> 2009; 20: 1535\u20131542.","DOI":"10.1093\/annonc\/mdp025"},{"key":"21","unstructured":"21. Wise J, Tiwari R, O\u2019Halloran S, Fleshner L, Nguyen S, Hersey K, et al. Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring. <i>Can J Urol<\/i> 2022; 29: 11136\u201311141."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of onco-hypertension and future perspectives. <i>Hypertension<\/i> 2021; 77: 16\u201327.","DOI":"10.1161\/HYPERTENSIONAHA.120.16044"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sahni G. Onco-hypertension: Changing paradigm of treating hypertension in patients with cancer. <i>J Clin Oncol<\/i> 2023; 41: 958\u2013963.","DOI":"10.1200\/JCO.22.01875"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: A real-life study and proposed algorithm for proactive management. <i>ESMO Open<\/i> 2022; 7: 100338.","DOI":"10.1016\/j.esmoop.2021.100338"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kaneko H, Yano Y, Lee H, Lee HH, Okada A, Suzuki Y, et al. Blood pressure classification using the 2017 ACC\/AHA guideline and heart failure in patients with cancer. <i>J Clin Oncol<\/i> 2023; 41: 980\u2013990.","DOI":"10.1200\/JCO.22.00083"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J<\/i> 2022; 43: 4229\u20134361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Camarda N, Travers R, Yang VK, London C, Jaffe IZ. VEGF Receptor inhibitor-induced hypertension: Emerging mechanisms and clinical implications. <i>Curr Oncol Rep<\/i> 2022; 24: 463\u2013474.","DOI":"10.1007\/s11912-022-01224-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Travers RJ, Stepanian A, Jaffe I. Endothelium as a source of cardiovascular toxicity from antitumor kinase inhibitors. <i>Arterioscler Thromb Vasc Biol<\/i> 2024; 44: 2143\u20132153.","DOI":"10.1161\/ATVBAHA.124.319864"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Qu Y, Liu ZX, Zheng XX, Wu SN, An JQ, Zou MH, et al. MFN2-mediated decrease in mitochondria-associated endoplasmic reticulum membranes contributes to sunitinib-induced endothelial dysfunction and hypertension. <i>J Mol Cell Cardiol<\/i> 2025; 200: 45\u201360.","DOI":"10.1016\/j.yjmcc.2025.01.005"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. <i>Hypertension<\/i> 2009; 54: 652\u2013658.","DOI":"10.1161\/HYPERTENSIONAHA.109.129973"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. <i>Hypertension<\/i> 2010; 56: 675\u2013681.","DOI":"10.1161\/HYPERTENSIONAHA.109.149690"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mirabito Colafella KM, Neves KB, Montezano AC, Garrelds IM, van Veghel R, de Vries R, et al. Selective ETA vs. dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. <i>Cardiovasc Res<\/i> 2020; 116: 1779\u20131790.","DOI":"10.1093\/cvr\/cvz260"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. <i>Ann Oncol<\/i> 2008; 19: 927\u2013934.","DOI":"10.1093\/annonc\/mdm550"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lankhorst S, Severs D, Marko L, Rakova N, Titze J, Muller DN, et al. Salt sensitivity of angiogenesis inhibition-induced blood pressure rise: Role of interstitial sodium accumulation? <i>Hypertension<\/i> 2017; 69: 919\u2013926.","DOI":"10.1161\/HYPERTENSIONAHA.116.08565"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Witte J, Muhlbauer M, Braun D, Steinbach A, Golchert J, Rettig R, et al. Renal soluble guanylate cyclase is downregulated in sunitinib-induced hypertension. <i>J Am Heart Assoc<\/i> 2018; 7: e009557.","DOI":"10.1161\/JAHA.118.009557"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Marko L, Dorr A, Linz P, van den Meiracker AH, Garrelds IM, Kuehne T, et al. Effect of sunitinib treatment on skin sodium accumulation in patients with renal cancer: A pilot study. <i>Hypertension<\/i> 2022; 79: e103\u2013e105.","DOI":"10.1161\/HYPERTENSIONAHA.122.19079"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. <i>J Natl Cancer Inst<\/i> 2011; 103: 763\u2013773.","DOI":"10.1093\/jnci\/djr128"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Szmit S, Langiewicz P, Zlnierek J, Nurzynski P, Zaborowska M, Filipiak KJ, et al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. <i>Kidney Blood Press Res<\/i> 2012; 35: 18\u201325.","DOI":"10.1159\/000329933"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. <i>Clin Pharmacol Ther<\/i> 2012; 92: 503\u2013510.","DOI":"10.1038\/clpt.2012.136"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. <i>Ann Oncol<\/i> 2012; 23: 3180\u20133187.","DOI":"10.1093\/annonc\/mds179"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: Impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. <i>Ann Oncol<\/i> 2015; 26: 1128\u20131133.","DOI":"10.1093\/annonc\/mdv147"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, et al. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma? <i>Eur J Cancer<\/i> 2016; 53: 96\u2013104.","DOI":"10.1016\/j.ejca.2015.10.006"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Fukuda H, Kondo T, Iida S, Takagi T, Tanabe K. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma. <i>Urol Oncol<\/i> 2016; 34: 338.e1\u2013e9.","DOI":"10.1016\/j.urolonc.2016.03.010"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Liu Y, Zhou L, Chen Y, Liao B, Ye D, Wang K, et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. <i>BMC Urol<\/i> 2019; 19: 49.","DOI":"10.1186\/s12894-019-0481-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>Cancer<\/i> 2012; 118: 1946\u20131954.","DOI":"10.1002\/cncr.26491"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. <i>Hypertension<\/i> 2012; 60: 607\u2013615.","DOI":"10.1161\/HYPERTENSIONAHA.112.196774"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T, et al. Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: A potential marker for better prognosis. <i>Hypertens Res<\/i> 2025; 48: 1542\u20131553.","DOI":"10.1038\/s41440-025-02149-4"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension and clinical outcome with bevacizumab: Results from 7 phase III studies. <i>Oncologist<\/i> 2013; 18: 273\u2013280.","DOI":"10.1634\/theoncologist.2012-0339"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. <i>Nature<\/i> 1993; 362: 841\u2013844.","DOI":"10.1038\/362841a0"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. <i>Science<\/i> 2005; 307: 58\u201362.","DOI":"10.1126\/science.1104819"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. <i>Cancer Res<\/i> 2013; 73: 2943\u20132948.","DOI":"10.1158\/0008-5472.CAN-12-4354"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: Tools or decorations? <i>Nat Clin Pract Oncol<\/i> 2008; 5: 378\u2013391.","DOI":"10.1038\/ncponc1150"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/8\/8_CR-26-0054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:29:21Z","timestamp":1786764561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/8\/8_CR-26-0054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0054","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"CR-26-0054"}}